These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 25425335

  • 1. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
    Ni YB, Tsang JY, Chan SK, Tse GM.
    Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
    Liu H, Shi J, Prichard JW, Gong Y, Lin F.
    Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
    [Abstract] [Full Text] [Related]

  • 3. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M, Pang JC, Jing X, Fields KL, Roh MH.
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [Abstract] [Full Text] [Related]

  • 4. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB, Tsang JYS, Shao MM, Chan SK, Cheung SY, Tong J, To KF, Tse GM.
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [Abstract] [Full Text] [Related]

  • 5. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
    Chia SY, Thike AA, Cheok PY, Tan PH.
    Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
    [Abstract] [Full Text] [Related]

  • 6. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.
    Luo MH, Huang YH, Ni YB, Tsang JY, Chan SK, Shao MM, Tse GM.
    Hum Pathol; 2013 Jul; 44(7):1241-50. PubMed ID: 23332923
    [Abstract] [Full Text] [Related]

  • 7. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y, Lu S, Zeng W, Xie S, Xiao S.
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [Abstract] [Full Text] [Related]

  • 8. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
    Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E, Dietel M, Kristiansen G.
    Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
    [Abstract] [Full Text] [Related]

  • 9. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM, Mentrikoski MJ, Wick MR.
    Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
    [Abstract] [Full Text] [Related]

  • 10. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
    Hou Y, Shen R, Chaudhary S, Tonkovich D, Li Z.
    Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
    [Abstract] [Full Text] [Related]

  • 11. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH, Shaaban HM.
    Turk Patoloji Derg; 2018 Oct; 34(2):143-149. PubMed ID: 29235613
    [Abstract] [Full Text] [Related]

  • 12. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin.
    Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, Argani P.
    Am J Clin Pathol; 2011 Apr; 135(4):587-91. PubMed ID: 21411781
    [Abstract] [Full Text] [Related]

  • 13. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
    Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT.
    Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
    [Abstract] [Full Text] [Related]

  • 14. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
    Braxton DR, Cohen C, Siddiqui MT.
    Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
    [Abstract] [Full Text] [Related]

  • 15. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW, Papadimos DJ, Walsh MD.
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [Abstract] [Full Text] [Related]

  • 16. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
    Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, Sakamoto G.
    APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
    [Abstract] [Full Text] [Related]

  • 17. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
    Cakir A, Isik Gonul I, Ekinci O, Cetin B, Benekli M, Uluoglu O.
    Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
    [Abstract] [Full Text] [Related]

  • 18. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G.
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [Abstract] [Full Text] [Related]

  • 19. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
    Liu X, Feng C, Liu J, Zhao L, Liu J, Zhang W, Liu N, Niu Y.
    Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
    [Abstract] [Full Text] [Related]

  • 20. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Taketani K, Aishima S, Oda Y, Morita M, Maehara Y.
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.